The CALGB/Alliance 50303 phase III trial of DA‐EPOCH showed no differences in EFS or OS in the DLBCL population as a whole, but subset analysis by FISH and IHC has yet to be reported, and will unlikely be able to answer this question due to low populations of DH/THL in the study. Enter your email address below and we will send you your username, If the address matches an existing account you will receive an email with instructions to retrieve your username, Overlap of DLBCL subtypes by COO and molecular features, ANNUAL CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES, I have read and accept the Wiley Online Library Terms and Conditions of Use, Salvage regimens with autologous transplantation for relapsed large B‐cell lymphoma in the rituximab era, The International Non‐Hodgkin's Lymphoma Prognostic Factors, A predictive model for aggressive non‐Hodgkin's lymphoma, Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes, Genetics and pathogenesis of Diffuse large B‐cell lymphoma, Genetic and functional drivers of diffuse large B cell lymphoma, The 2016 revision of the World Health Organization classification of lymphoid neoplasms, CD30 expression defines a novel subgroup of diffuse large B‐cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab‐CHOP Consortium Program Study, Inferior survival in high‐grade B‐cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements, Distinct types of diffuse large B‐cell lymphoma identified by gene expression profiling, Gene‐expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B‐cell lymphoma treated with immunochemotherapy, Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B‐cell lymphoma in the RICOVER‐60 trial of the DSHNHL, Prognostic significance of diffuse large B‐cell lymphoma cell of origin determined by digital gene expression in formalin‐fixed paraffin‐embedded tissue biopsies, Clinical impact of the cell‐of‐origin classification and the MYC/BCL2 dual expresser status in diffuse large B‐cell lymphoma treated within prospective clinical trials of the German high‐grade non‐Hodgkin's lymphoma study group, Relapsed or refractory double‐expressor and double‐hit lymphomas have inferior progression‐free survival after autologous stem‐cell transplantation, Clinical significance of co‐expression of MYC and BCL2 protein in aggressive B‐cell lymphomas treated with a second line immunochemotherapy, MYC/BCL2 protein coexpression contributes to the inferior survival of activated B‐cell subtype of diffuse large B‐cell lymphoma and demonstrates high‐risk gene expression signatures: a report from The International DLBCL Rituximab‐CHOP Consortium Program, High grade B‐cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B‐cell lymphoma morphology, Double‐hit gene expression signature defines a distinct subgroup of germinal center B‐cell‐like diffuse large B‐cell lymphoma, Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B‐cell lymphoma in the rituximab era, An enhanced International Prognostic Index (NCCN‐IPI) for patients with diffuse large B‐cell lymphoma treated in the rituximab era, The use of molecular profiling to predict survival after chemotherapy for diffuse large‐B‐cell lymphoma, The germinal center/activated B‐cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B‐cell lymphoma: a bio‐CORAL study, Cell of origin fails to predict survival in patients with diffuse large B‐cell lymphoma treated with autologous hematopoietic stem cell transplantation, Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL, Diffuse large B‐cell lymphoma with primary treatment failure: ultra‐high risk features and benchmarking for experimental therapies, Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B‐cell lymphoma treated in the era of rituximab, MYC gene rearrangements are associated with a poor prognosis in diffuse large B‐cell lymphoma patients treated with R‐CHOP chemotherapy, MYC‐IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study, Prognostic significance of MYC single, double, triple hit and MYC‐translocation partner status in diffuse large B‐cell lymphoma ‐ a study by the Lunenburg lymphoma biomarker consortium (LLBC); ASH Annual Meeting, Double hit lymphoma: the MD Anderson Cancer Center clinical experience, Impact of induction regimen and stem cell transplantation on outcomes in double‐hit lymphoma: a multicenter retrospective analysis, Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations, Concurrent expression of MYC and BCL2 in diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone, Immunohistochemical double‐hit score is a strong predictor of outcome in patients with diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone, MYC+ diffuse large B‐cell lymphoma is not salvaged by classical R‐ICE or R‐DHAP followed by BEAM plus autologous stem cell transplantation, Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B‐cell non‐Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14‐day versus 21‐day cycles, Dose‐dense rituximab‐CHOP compared with standard rituximab‐CHOP in elderly patients with diffuse large B‐cell lymphoma (the LNH03‐6B study): a randomised phase 3 trial, Obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B‐cell lymphoma: final results from an open‐label, randomized phase 3 study (GOYA), Phase III randomized study of R‐CHOP versus DA‐EPOCH‐R and molecular analysis of untreated diffuse large B‐cell lymphoma: CALGB/Alliance 50303, Precision treatment of distinct molecular subtypes of diffuse large B‐cell lymphoma: ascribing treatment based on the molecular phenotype, Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP) for treatment‐naive patients with CD20‐positive B‐cell non‐Hodgkin lymphoma: a non‐randomised, phase 1b study, Bortezomib plus CHOP‐rituximab for previously untreated diffuse large B‐cell lymphoma and mantle cell lymphoma, Randomized phase II study of R‐CHOP with or without Bortezomib in previously untreated patients with non‐germinal center B‐cell‐like diffuse large B‐cell lymphoma, Lenalidomide combined with R‐CHOP overcomes negative prognostic impact of non–germinal center B‐cell phenotype in newly diagnosed diffuse large B‐cell lymphoma: a phase II study, CUDC‐907 in relapsed/refractory diffuse large B‐cell lymphoma, including patients with MYC‐alterations: results from an expanded phase I trial, Front‐line, dose‐escalated immunochemotherapy is associated with a significant progression‐free survival advantage in patients with double‐hit lymphomas: a systematic review and meta‐analysis, Outcomes of patients with double‐hit lymphoma who achieve first complete remission, Outcome of patients with double‐expressor lymphomas (DELs) treated with R‐CHOP or R‐EPOCH, High risk diffuse large B cell lymphoma: a comparison of aggressive subtypes treated with dose adjusted chemotherapy—the University of Texas MD Anderson experience, Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy‐sensitive non‐Hodgkin's lymphoma, Outcomes of primary refractory diffuse large B‐cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era, Outcome of patients with relapsed diffuse large B‐cell lymphoma who fail second‐line salvage regimens in the International CORAL study, Outcomes of diffuse large B‐cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study, Outcomes in refractory diffuse large B‐cell lymphoma: results from the international SCHOLAR‐1 study, Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma, A multi‐institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib, A phase I study of Ibrutinib in combination with R‐ICE in patients with relapsed or primary refractory DLBCL, Molecular mechanisms of disease progression in primary cutaneous diffuse large B‐cell lymphoma, leg type during Ibrutinib therapy, BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild‐type MYD88‐mutated cells by a paracrine mechanism, Lenalidomide monotherapy in relapsed or refractory aggressive non‐Hodgkin's lymphoma, An international phase II trial of single‐agent lenalidomide for relapsed or refractory aggressive B‐cell non‐Hodgkin's lymphoma, A phase 2/3 multicenter, randomized, open‐label study to compare the efficacy and safety of Lenalidomide versus Investigator's choice in patients with relapsed or refractory diffuse large B‐cell lymphoma, Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN), Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide, Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial, Long‐term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B‐cell lymphoma patients, Lenalidomide maintenance in patients with relapsed diffuse large B‐cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single‐arm, multicentre phase 2 trial, Differential efficacy of bortezomib plus chemotherapy within molecular subtypes, AMC‐053: pilot study of an oncolytic viral strategy using Bortezomib with ICE +/− rituximab for relapsed/refractory HIV+ lymphomas, C‐MYC‐positive relapsed and refractory, diffuse large B‐cell lymphoma: impact of additional "hits" and outcomes with subsequent therapy, Tisagenlecleucel in adult relapsed or refractory diffuse large B‐cell lymphoma, Axicabtagene Ciloleucel CAR T‐cell therapy in refractory large B‐cell lymphoma, Axicabtagene Ciloleucel (Axi‐Cel) CD19 Chimeric Antigen Receptor (CAR) T‐Cell Therapy for Relapsed/Refractory Large B‐Cell Lymphoma: Real World Experience, Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity, Allogeneic haematopoietic stem‐cell transplantation for relapsed and refractory aggressive histology non‐Hodgkin lymphoma. Fan, Y., Artz, A.S., van Besien, K. et al. - And More, Close more info about Stem Cell Transplantation and Long-Term Survival in Patients With Amyloid Light-Chain Amyloidosis, Symptom Burden in Polycythemia Vera Unrelated to Controlled Blood Counts, Depressive Symptoms May Be Associated With Survival in Patients With Hematologic Malignancies, Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. The median follow-up was 17.1 years.


John Lennon - Imagine Discogs, Andrea Gibson Lakewood, How To Get 5 Star Weak Foot Fifa 20 Career, Wireless Microphone Headset System, Thomas Durst, Neon Vernacular Pdf, Camp Averno Location, Taiwan National Bird, How To Treat Felon Finger Infection At Home, Holistic Gastroenterologist, Similarities Between Christianity And Paganism, I've Got You Under My Skin Cover, Sta Travel Clinic Manchester, Azure-winged Magpie Call, Pua Unemployment Nc Extension, Bjp Mp List 2019, Santa Claus Is Comin' To Town! Wii, Lose 5 Pounds In A Week Meal Plan, Westmoreland County Recorder Of Deeds, Rufous Treepie In Malayalam, Buster And Punch Nyc, 3rd Amendment Court Cases, Not For The Life Of Me Piano Backing Track, Jordan Foster Construction Revenue, Andhra Pradesh Election Results 2019, Hook Of Holland To Rotterdam, Swissquote Expat Account Review, Interesting Facts About Clive King, Sta Travel Clinic Manchester, Zen Buddhism Meaning, Karnataka Mla List 2019 Party Wise, Bbc Thriller Series 2020, Wallabies Rugby Bledisloe Cup, Venn Diagram Questions, Helena Almeida Photography, Government Information Technology Salary, Margaret Joyce, The Selection Series Order To Read,